Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a debilitating pulmonary disorder with systemic effects, and it is the fourth leading cause of death in the United States. COPD patients not only develop respiratory limitations, but can also demonstrate systemic wasting, features of depression, and ca...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Pulmonary Medicine |
Online Access: | http://dx.doi.org/10.1155/2011/257496 |
id |
doaj-b6b1751fc62b4c508333f872abb5f1a7 |
---|---|
record_format |
Article |
spelling |
doaj-b6b1751fc62b4c508333f872abb5f1a72020-11-24T23:04:28ZengHindawi LimitedPulmonary Medicine2090-18362090-18442011-01-01201110.1155/2011/257496257496Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary DiseaseRokhsara Rafii0Timothy E. Albertson1Samuel Louie2Andrew L. Chan3Division of Pulmonary, Critical Care and Sleep Medicine, UC Davis School of Medicine and VA Northern California Health Care System, 4150 V Street, Suite 3400, Sacramento, CA 95817, USADivision of Pulmonary, Critical Care and Sleep Medicine, UC Davis School of Medicine and VA Northern California Health Care System, 4150 V Street, Suite 3400, Sacramento, CA 95817, USADivision of Pulmonary, Critical Care and Sleep Medicine, UC Davis School of Medicine, 4150 V Street, Suite 3400, Sacramento, CA 95817, USADivision of Pulmonary, Critical Care and Sleep Medicine, UC Davis School of Medicine and VA Northern California Health Care System, 4150 V Street, Suite 3400, Sacramento, CA 95817, USAChronic obstructive pulmonary disease (COPD) is a debilitating pulmonary disorder with systemic effects, and it is the fourth leading cause of death in the United States. COPD patients not only develop respiratory limitations, but can also demonstrate systemic wasting, features of depression, and can succumb to social isolation. Smoking cessation is crucial, and pharmacotherapy with bronchodilators is helpful in symptom management. Inhaled corticosteroids may be beneficial in some patients. In addition, pulmonary rehabilitation and palliative care are important components under the right clinical circumstance. This review highlights current guidelines and management strategies for COPD and emphasizes novel pharmacotherapy and minimally invasive (nonsurgical) lung-volume reduction interventions that may prove to be of significant benefit in the future.http://dx.doi.org/10.1155/2011/257496 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rokhsara Rafii Timothy E. Albertson Samuel Louie Andrew L. Chan |
spellingShingle |
Rokhsara Rafii Timothy E. Albertson Samuel Louie Andrew L. Chan Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease Pulmonary Medicine |
author_facet |
Rokhsara Rafii Timothy E. Albertson Samuel Louie Andrew L. Chan |
author_sort |
Rokhsara Rafii |
title |
Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease |
title_short |
Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease |
title_full |
Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease |
title_fullStr |
Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease |
title_full_unstemmed |
Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease |
title_sort |
update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease |
publisher |
Hindawi Limited |
series |
Pulmonary Medicine |
issn |
2090-1836 2090-1844 |
publishDate |
2011-01-01 |
description |
Chronic obstructive pulmonary disease (COPD) is a debilitating pulmonary disorder with systemic effects, and it is the fourth leading cause of death in the United States. COPD patients not only develop respiratory limitations, but can also demonstrate systemic wasting, features of depression, and can succumb to social isolation. Smoking cessation is crucial, and pharmacotherapy with bronchodilators is helpful in symptom
management. Inhaled corticosteroids may be beneficial in some patients. In addition, pulmonary rehabilitation and palliative care are important components under the right clinical circumstance. This review highlights current guidelines and management strategies for COPD and emphasizes novel pharmacotherapy and minimally invasive (nonsurgical) lung-volume reduction interventions that may prove to be of significant benefit in the future. |
url |
http://dx.doi.org/10.1155/2011/257496 |
work_keys_str_mv |
AT rokhsararafii updateonpharmaceuticalandminimallyinvasivemanagementstrategiesforchronicobstructivepulmonarydisease AT timothyealbertson updateonpharmaceuticalandminimallyinvasivemanagementstrategiesforchronicobstructivepulmonarydisease AT samuellouie updateonpharmaceuticalandminimallyinvasivemanagementstrategiesforchronicobstructivepulmonarydisease AT andrewlchan updateonpharmaceuticalandminimallyinvasivemanagementstrategiesforchronicobstructivepulmonarydisease |
_version_ |
1725630214582566912 |